{
    "root": "5d4b1d8d-6e91-42aa-bc00-454a8cf4d30a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Finasteride",
    "value": "20250512",
    "ingredients": [
        {
            "name": "FINASTERIDE",
            "code": "57GNO57U7G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5062"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": {
        "text": "finasteride tablets , 5\u03b1-reductase inhibitor , indicated treatment symptomatic benign prostatic hyperplasia ( bph ) men enlarged prostate ( 1.1 ) : \u2022 improve symptoms \u2022 reduce risk acute urinary retention \u2022 reduce risk need surgery including transurethral resection prostate ( turp ) prostatectomy . finasteride tablets administered combination alpha-blocker doxazosin indicated reduce risk symptomatic progression bph ( confirmed \u2265 4 point increase american urological association ( aua ) symptom score ) ( 1.2 ) . limitations : finasteride tablets approved prevention prostate cancer ( 1.3 ) .",
        "doid_entities": [
            {
                "text": "prostate cancer (DOID:10283)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10283"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute urinary retention",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_71198"
            }
        ]
    },
    "contraindications": {
        "text": "finasteride tablets may administered without meals .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "finasteride tablets , usp 5 mg available blue colored , 7 mm round , biconvex , film coated tablets , marked \u201c f5 \u201d one side plain side . supplied follows : ndc68788-8433-3 , bottles 30 tablets ndc68788-8433-6 , bottles 60 tablets ndc68788-8433-9 , bottles 90 tablets ndc68788-8433-1 , bottles 100 tablets storage handling store room temperatures 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) . [ usp controlled room temperature ] . protect light keep container tightly closed . females handle crushed broken finasteride tablets pregnant may potentially pregnant possibility absorption finasteride subsequent potential risk male fetus [ ( 5.3 ) ( 8.1 ) ] .",
    "adverseReactions": "finasteride tablets contraindicated following : \u2022hypersensitivity component medication . \u2022pregnancy . finasteride contraindicated females may potentially pregnant . ability type ii 5\u03b1-reductase inhibitors inhibit conversion testosterone 5\u03b1-dihydrotestosterone ( dht ) , finasteride may cause abnormalities external genitalia male fetus pregnant female receives finasteride . used pregnancy , pregnancy occurs taking , pregnant female apprised potential hazard male fetus . [ also ( 5.3 ) , ( 8.1 ) , supplied/storage handling ( 16 ) . ] female rats , low doses finasteride administered pregnancy produced abnormalities external genitalia male offspring .",
    "indications_original": "Finasteride tablets, are a 5\u03b1-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to ( 1.1 ): \u2022 Improve symptoms \u2022 Reduce the risk of acute urinary retention \u2022 Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Finasteride tablets administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed \u2265 4 point increase in American Urological Association (AUA) symptom score) ( 1.2 ). Limitations of Use: Finasteride tablets are not approved for the prevention of prostate cancer ( 1.3 ).",
    "contraindications_original": "Finasteride tablets\u00a0may be administered with or without meals.",
    "warningsAndPrecautions_original": "Finasteride tablets, USP 5 mg are available as blue colored, 7 mm round, biconvex, film coated tablets, marked \u201cF5\u201d on one side and plain on other side.\u00a0They are supplied as follows:\n                  NDC68788-8433-3, bottles of\u00a030 tablets\n                     NDC68788-8433-6, bottles of\u00a060 tablets\n                     NDC68788-8433-9, bottles of\u00a090 tablets\n                  NDC68788-8433-1, bottles of\u00a0100 tablets\n                     \n                     Storage and Handling \n                  \n                  \u00a0\u00a0\n                  Store at room temperatures 20\u00b0C to\u00a025\u00b0C\u00a0(68\u00b0F to 77\u00b0F). [See USP Controlled Room Temperature]. Protect from light and keep container tightly closed.\n                  Females should not handle crushed or broken finasteride tablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus\u00a0[see Warnings and Precautions (5.3) and\u00a0Use in Specific Populations (8.1)].",
    "adverseReactions_original": "Finasteride tablets are\u00a0contraindicated in the following:\n                  \n                     \n                        \u2022Hypersensitivity to any component of this medication.\n                     \n                        \u2022Pregnancy. Finasteride use is contraindicated in females when they are or may potentially be pregnant. Because of the ability of Type II 5\u03b1-reductase inhibitors to inhibit the conversion of testosterone to 5\u03b1-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant\u00a0female\u00a0who receives finasteride. If this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant\u00a0female should be apprised of the potential hazard to the male fetus. [See also Warnings and Precautions (5.3), Use in Specific Populations (8.1), and\u00a0How Supplied/Storage and Handling (16).] In female rats, low doses of finasteride administered during pregnancy have produced abnormalities of the external genitalia in male offspring.",
    "drug": [
        {
            "name": "Finasteride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5062"
        }
    ]
}